GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Updated November 7, 2026 | v7.4

Renal updates by clinical finding

Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.

Reset

Search all 1,215 records | Source cautions

Dose or interval change

Dofetilide (Tikosyn), oral capsule

Renal measure
Cockcroft-Gault CrCl with actual body weight, mL/min
Renal action or finding
Initial oral doses by calculated CrCl are 500 mcg twice daily above 60, 250 mcg twice daily at 40-60, and 125 mcg twice daily at 20 to below 40 mL/min. Below 20, use is contraindicated.
Limits and monitoring
Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 30, posted Apr 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Enalaprilat (Enalaprilat), IV injection

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
At CrCl 30 mL/min or less, start IV enalaprilat at 0.625 mg. The usual IV dose at clearance above 30 is 1.25 mg every six hours.
Limits and monitoring
Reassess pressure and renal response after the initial dose. Oral conversion has separate instructions.

Verify the current prescribing information for this presentation.

DailyMed SPL version 1, posted Mar 13, 2008 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Enalapril maleate (Vasotec), oral tablet

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
For adult hypertension with CrCl 30 mL/min or less, the recommended first oral enalapril dose is 2.5 mg once daily. Above 30, the usual initial regimen applies.
Limits and monitoring
Dialysis days, heart failure, baseline hypotension and diuretic use have separate considerations.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 15, posted Jan 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Enoxaparin sodium (Lovenox), adult subcutaneous prophylaxis and DVT treatment

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
For adult CrCl below 30 mL/min, labeled abdominal surgery, hip/knee replacement, and acutely ill medical prophylaxis use 30 mg SC daily. Labeled DVT treatment with warfarin uses 1 mg/kg SC daily.
Limits and monitoring
ACS and STEMI have indication- and age-specific instructions. Assess bleeding and neuraxial procedure timing separately.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 33, posted May 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Famciclovir (Famvir), oral tablets; generic label comparison

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
For immunocompetent adults with herpes zoster, use 500 mg every 8 hours at CrCl at least 60, every 12 hours at 40-59, and every 24 hours at 20-39 mL/min. Below 20, give 250 mg every 24 hours. In HD give 250 mg following each dialysis session.
Limits and monitoring
The usual course is seven days. Genital and orolabial herpes use different regimens. The primary source is a matched generic oral tablet label.

The RX source names Famvir. The separately linked prescribing information is for a generic famciclovir oral tablet of matching form and strength.

DailyMed SPL version 4, posted Jan 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Foscarnet sodium (Foscavir), IV injection

Renal measure
Body-weight-normalized CrCl, mL/min/kg
Renal action or finding
Select maintenance and induction doses from the indication-specific table using CrCl in mL/min/kg. Measure renal function frequently, adjust when it changes, and provide labeled hydration.
Limits and monitoring
An absolute CrCl in mL/min cannot be entered directly into this table. Monitor calcium, magnesium, potassium and phosphate.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 16, posted Dec 12, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Hydromorphone hydrochloride (Dilaudid), IV, IM or subcutaneous injection

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity.
Limits and monitoring
Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 6, posted Aug 31, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Hydroxyurea (Hydrea), oral capsule

Renal measure
Measured creatinine clearance, mL/min
Renal action or finding
At measured CrCl below 60 mL/min or in ESRD, reduce the initial once-daily dose from 15 to 7.5 mg/kg. Give after hemodialysis on dialysis days.
Limits and monitoring
Monitor blood counts closely. Confirm Hydrea and its labeled indication before applying the regimen.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 21, posted Jan 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Hydroxyurea (Siklos), oral tablets for sickle cell disease

Renal measure
Measured creatinine clearance, mL/min
Renal action or finding
Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days.
Limits and monitoring
Verify the age-specific initial dose, tablet strength and hematologic monitoring.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 13, posted Jan 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Imipenem and cilastatin sodium (Primaxin I.V.), IV injection

Renal measure
Cockcroft-Gault CrCl, mL/min
Renal action or finding
Adult CrCl below 90 mL/min requires a lower imipenem/cilastatin IV regimen. Use the label's renal table and the row for the intended regimen and organism susceptibility.
Limits and monitoring
Use stable serum creatinine. The label restricts use below CrCl 15 unless hemodialysis is instituted within 48 hours. Confirm seizure risk and HD timing.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 35, posted Oct 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Lamivudine (Epivir), oral HIV treatment; adults and adolescents at least 25 kg

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
For HIV treatment in adults and adolescents at least 25 kg, reduce lamivudine dosing below CrCl 50 mL/min. At 30-49 mL/min give 150 mg daily; lower bands have distinct first and maintenance doses.
Limits and monitoring
Routine four-hour HD or peritoneal dialysis requires no additional dose. Use the HIV product's renal table, not the HBV product regimen.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 24, posted Sep 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Lamotrigine (Lamictal), oral tablet

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
Select the initial lamotrigine schedule from the concomitant antiseizure regimen. Significant renal impairment may permit a lower maintenance dose.
Limits and monitoring
Verify the release form. Titration and restarting precautions remain essential because of serious rash risk.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 45, posted Aug 20, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

RX coverage and remaining workload | Previous 90-product roundup
Top